ASH Award for Research Careers in Hematology (ARCH) Recipients

The following individuals participated in the ASH Award for Research Careers in Hematology (ARCH) program, the successor to the ASH Bridge Grant Program.

2026

  • Sophia Adamia, PhD, Beth Israel Deaconess Medical Center, The CD38 RNA Therapeutics: A Strategy to Reverse Antigen Escape in Relapsed Myeloma
  • Connie Arthur, PhD, Brigham & Women's Hospital, Immunologic Consequences of Neonatal Anemia and Its Treatment
  • Nitya Bakshi, MBBS, MS, Yale School of Medicine, Plasma Proteomic Biomarkers of Sickle Cell Disease Pain
  • Tessa Barrett, PhD, New York University Grossman School of Medicine, Platelet KLHDC8B as a Regulator of Thromboinflammatory Thrombosis
  • Linda Baughn, PhD, Mayo Clinic, Aging and Immune Senescence Drive Racial Disparities in Multiple Myeloma
  • Shannon Buckley, PhD, University of Utah, Deciphering Genes Associated with Trisomy 8
  • Sheng Cai, MD, PhD, Memorial Sloan Kettering, Concurrent Menin Inhibition and Ikaros Degradation to Overcome Resistance in Relapsed Acute Leukemia
  • Jaebok Choi, MA, PhD, The Washington University, Targeting the GAS6-TAM Axis to Prevent GvHD and Leukemia Relapse
  • Marta Derecka, PhD, St. Jude Childre's Research Hospital, Elucidating Therapeutic Potential of ITGB8 Inhibition in Myelofibrosis
  • Francesca Ferraro, MD, PhD, The Washington University, Mechanisms and Therapeutic Targeting of Immune Dysfunction in Acute Myeloid Leukemia
  • Jacqueline Garcia, MD, Dana-Farber Cancer Insitute, Treatment Selection Using Dynamic BH3 Profiling in Patients with Relapsed or Refractory Acute Myeloid Leukemia
  • Heather Gustafson, PhD, Seattle Children's Research Institute, Mechanism-Based Prevention of CAR-T Neurotoxicity Through JAK2-Directed Immune Reprogramming
  • Rimi Hazra, PhD, The University of Pittsburgh, Hemolysis Driven CRH-FKBP5 Axis as a Mechanistic Driver for White Matter Injury and Cognitive Impairment in Sickle Cell Disease
  • R. Katherine Hyde, PhD, University of Nebraska Medical Center, Evaluation of the Nanoparticle PAMD-Ch17 as an Anti-leukemic and siRNA Delivery Agent
  • Seethal Jacob, MD, MS, Trustees of Indiana University, Determinants of Access to Neurocognitive Services in Sickle Cell Disease: The Role of Caregiver Recognition
  • Milka Koupenova, PhD, University of Massachusetts Chan Medical School, Mechanisms of Platelet Alarmin Release and Immunothrombosis
  • Mondira Kundu, MD, PhD, St. Jude Childre's Research Hospital, Mechanisms of SEC24C-Associated Dyserythropoiesis in Fetal and Stress Erythropoiesis
  • Rui Lu, PhD, University of Alabama at Birmingham, Defining a Non-catalytic Epigenetic Cofactor Dependency in Acute Myeloid Leukemia
  • Patrick McGann, MD, PhD, Rhode Island Hospital, Nationwide Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Angola
  • Carol Miao, PhD, Seattle Children's Research Institute, Redosable Nonviral Gene Therapy for Hemophilia A treatment
  • Betty Pace, MD, Augusta University, Gamma Globin Activation via Disruption of a Cis-Regulatory Element During Erythropoiesis in Sickle Cell Disease
  • Robert Paulson, PhD, The Pennsylvania State University, Role of Polyamines in Stress Erythropoiesis
  • Malini Raghavan, PhD, MSc, University of Michigan, Calreticulin Mutations in Myeloproliferative Neoplasms
  • Sunil Raikar, MD, Emory University, Understanding Lineage Plasticity and Improving Therapeutic Options for Pediatric B/Myeloid Mixed Phenotype Acute Leukemia
  • Sarah Reeves, PhD, MPH, University of Michigan, Advancing Quality Measurement to Improve Evidence-Based Care for Sickle Cell Disease Across the Lifespan
  • Marlies Rossmann, MD, PhD, University of Rochester, Role of Ferroptosis Suppression in Erythropoiesis
  • Kathleen Sakamoto, MD, PhD, Board of Trustees of the Leland Stanford Junior University, Repurposing Niclosamide for Treatment of Acute Myeloid Leukemia
  • Chunhua Song, DPhil, MD, The Ohio State University, Targeting Tumor Microenvironment to Reverse Immune Suppression in High-Risk T-ALL
  • Athena Starlard-Davenport, PhD, University of Tennessee Health Science Center, Systems Genetics of Sickle Cell Disease: Mapping Genetic Modifiers of Disease Severity Using the SCD-BXD Mouse Resource
  • Chih-Chia Su, PhD, Case Western Reserve University, Calcium-Regulated Control of Alternative Pathway Initiation: A New Paradigm in Complement Biology
  • Victor Tkachev, PhD, Massachusetts General Hospital, The Gut-Leukemia Axis After Bone Marrow Transplantation
  • Venee Tubman, MD, MMSc, Baylor College of Medicine, Mechanisms of B Lymphocyte Deficiency in Sickle Cell Disease
  • Nan Zhu, PhD, J Craig Venter Institute, Targeting BAF Chromatin Remodeling Complex in Acute Myeloid Leukemia
ASH-Johnson & Johnson ARCH Recipients
  • Heather Gustafson, PhD, Seattle Children's Research Institute, Mechanism-Based Prevention of CAR-T Neurotoxicity Through JAK2-Directed Immune Reprogramming
  • Sophia Adamia, PhD, Beth Israel Deaconess Medical Center, The CD38 RNA Therapeutics: A Strategy to Reverse Antigen Escape in Relapsed Myeloma
ASH-Regeneron ARCH Recipient
  • Linda Baughn, PhD, Mayo Clinic, Aging and Immune Senescence Drive Racial Disparities in Multiple Myeloma
Dr. Swee Lay Thein ARCH Recipient
  • Venee Tubman, MD, MMSc, Baylor College of Medicine, Mechanisms of B Lymphocyte Deficiency in Sickle Cell Disease

2025

  • Janis Abkowitz, MD, University of Washington, Contributions of aberrant heme-iron trafficking to MDS anemia
  • Joseph Aslan, PhD, Oregon Health & Science University, Pathway maps of platelet phenotype and function
  • Leslie Crews, PhD, The Regents of the University of California, San Diego, Core molecular regulators of lipid homeostasis in hematopoietic progenitor cell aging
  • Agnieszka Czechowicz, MD, Stanford University, Understanding HSC protection in bone marrow conditioning
  • David Dominguez-Sola, MD, PhD, Icahn School of Medicine at Mount Sinai, Discovery of a metabolic escape program advancing targeted therapeutics in Burkitt lymphoma
  • Michael Elliott, PhD, University of South Alabama, Cytotoxic capacity of antibody-mediated phagocytosis
  • Steven Josefowicz, PhD, Weill Cornell Medical Center, Central innate immune memory in BCG induced tumor immunity: mechanisms and predictors of patient response
  • Peter Klein, MD, PhD, Perelman School of Medicine at University of Pennsylvania, Targeting mitophagy through PINK1 splicing in MDS
  • Ying Liang, MD, PhD, New York Blood Center Enterprises, Sex dimorphism in bone marrow niche and its effect on hematopoietic transplantation
  • Peisong Ma, PhD, Thomas Jefferson University, GRK5 regulation of GPCR signaling in platelets
  • Punam Malik, MD, Cincinnati Children's Hospital Medical Center, Role of Fetal Hemoglobin in Hemoglobin-SC form of Sickle Cell Disease
  • Steven McKenzie, MD, PhD, Thomas Jefferson University, Inflammasome in HIT
  • Bethany Mundy-Bosse, PhD, The Ohio State University College of Medicine, The impact of TET2 dysfunction on immune surveillance and the development of myeloid disorder
  • Marvin Nieman, PhD, Case Western Reserve University, The role of protease activated receptors on platelets
  • Trista North, PhD, Boston Children's Hospital, Biomechanical activation of YAP induces hematopoietic stem cell production
  • Sarah O'Brien, MD, MSc, Research Institute at Nationwide Children's Hospital, Mobile app technology for identification of abnormal uterine bleeding in early adolescents
  • Hideyuki Oguro, PhD, University of Connecticut, The role of estrogen receptor signaling in clonal hematopoiesis
  • Vikram Paralkar, MD, Perelman School of Medicine at University of Pennsylvania, Regulation of RNA Polymerase I by myeloid transcription factor CEBPA
  • Seema Patel, PhD, Emory University, Dissecting the germinal center and extrafollicular B cell response to FVIII
  • Joel Pomerantz, PhD, Johns Hopkins University School of Medicine, Mechanisms of control of lymphocyte activation and proliferation by a critical signaling integrator
  • Neil Shah, MD, PhD, University of California, San Francisco, Defining mechanisms of on-target in vitro and clinical resistance to the first highly active allosteric kinase inhibitor
  • Aristotelis Tsirigos, PhD, New York University Grossman School of Medicine, Identify and target epigenetic clones in acute leukemia using combined in silico and in vivo approaches
  • Edmund Waller, MD, PhD, Emory University, Protective role of indoles derived from the commensal microbiota in GvHD
  • Marcin Wlodarski, MD, St. Jude Children’s Research Hospital, Deciphering the mechanisms of SAMD9L mutations in bone marrow failure
  • Feng-Chun Yang, MD, PhD, The University of Texas Health Science Center at San Antonio, The molecular mechanisms underlying PHF6-mutation-mediated hematologic malignancies